

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drugs In Development, 2021

<https://marketpublishers.com/r/TDD5C6DA43DAEN.html>

Date: December 2021

Pages: 144

Price: US\$ 3,500.00 (Single User License)

ID: TDD5C6DA43DAEN

Abstracts

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drugs In Development, 2021

SUMMARY

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni²⁺. Its responses are triggered by Ni²⁺ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 45 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 3, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Undisclosed, Dermatology, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Bacterial Sepsis, Chronic Liver Disease, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non

Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Allergic Asthma, Allergic Rhinitis, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Hearing Disorders, Hepatic Injury, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritonitis, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rheumatoid Arthritis, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Rare Disease and Viral Respiratory Tract Infection.

The latest report Toll Like Receptor 4 – Drugs In Development, 2021, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dormant Products, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/TDD5C6DA43DAEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TDD5C6DA43DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970